9 / 10
Journal of Preventive Medicine
ISSN: 2572-5483
July 16-17, 2018
London, UK
Preventive Medicine 2018
Page 34
9
th
Edition of International Conference on
Preventive Medicine
& Public Health
S
epsis is a life-threatening condition that results in 30%
mortality in critically ill patients, and many survivors are
with poor quality of life due to long-lasting impact of sepsis on
functional and cognitive limitations. There are no proven specific
pharmacotherapies for sepsis, and thus new approaches
are urgently needed. As our ability to identify the clinical and
biological heterogeneity in human sepsis expands, precision
medicine may hold the key to therapeutic breakthroughs. Recent
advances in molecular diagnostics and omics approaches have
great impact on precision medicine that is rapidly expanding.
However, precision medicine should not be limited to using just
omics based data. The key common approach is the recognition
that disease heterogeneity may have important implications for
clinical outcomes and for the effectiveness of novel therapies.
Biography
Haibo Zhang has completed his PhD fromFree University of Brussels, Belgium.
He is a Full-Professor of Anaesthesia, Critical Care Medicine and Physiology at
the Universityof Toronto, Canada. He is the Head of the Theme of Biomaterial,
Organ Injury and Repair, Institute of Biomedical Engineering Science and Tech-
nology (iBEST), a premier research organization operated by St. Michael’s Hos-
pital and Ryerson University, Toronto, Canada. He has publishedmore than 200
papers in reputed journals and has been serving as an Editorial Board Member
of repute journals.
zhangh@smh.caPrecision medicine in sepsis
Haibo Zhang
St. Michael’s Hospital - University of Toronto, Canada
Haibo Zhang, J Prev Med 2018, Volume 3
DOI: 10.21767/2572-5483-C1-001